Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

Also called NCT02988245

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02988245
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02988245. Randomized; single masking; primary purpose treatment. Start 2022-06 (anticipated); primary completion 2023-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension
Acronym
PGEN for HTN
Condition
Hypertension
Intervention (Drug)
Geneticure Panel for HTN therapy
Intervention (Drug)
JNC-8
Lead sponsor
Geneticure, LLC (class: industry)
Collaborator
Fairview Health Services (class: other)
Collaborator
University of Minnesota (class: other)

Record details

Record id
cardio:ct-nct02988245
Content hash
908c43d63abdc1267c2c7da61fc551a6ed39c8917b4bdb02c49ce9682f7bdeb7